Voixx lawsuit - Voixx tablets - Rofecoxib

web user gold award for britain.tv   translate to spanishtranslate to germantranslate to french

 

Search Britain.tv:

 
 
 

Bookmark and Share [Health >> Voixx lawsuit – Voixx tablets - Rofecoxib]

Voixx lawsuit – Voixx tablets - Rofecoxib

Vioxx(Voixx) Lawsuit - Merck Payout

The US pharmaceutical company Merck was ordered to pay $253.4m (£141m) to the widow of a man who died from a heart attack blamed on the popular painkiller Vioxx(Voixx).

What is Voixx/ Rofecoxib?

Rofecoxib/Vioxx is a nonsteroidal anti-inflammatory drug (NSAID) that was used in the treatment of osteoarthritis, acute pain conditions, and dysmenorrhoea.

Rofecoxib was one of the most widely used drugs ever to be withdrawn from the market. Worldwide, over two million people were prescribed Vioxx at the time. In the year before withdrawal, Merck had sales revenue of US$2.5 billion from Vioxx.

Rofecoxib was available on prescription as tablets and as an oral suspension.

COX-2 selective inhibitor

Rofecoxib belongs to the group of NSAIDs known as COX-2 selective inhibitors or coxibs (CycloOXygenase-2 InhiBitors). Being COX-2 selective means that these drugs act specifically on one form of the cyclooxygenase (COX) enzyme, namely the COX-2, whereas previous NSAIDs inhibited both COX-1 and COX-2. This specificity allows rofecoxib and other COX-2 inhibitors to reduce inflammation and pain while minimizing undesired gastrointestinal adverse effects - peptic ulcers - that are common with non-selective NSAIDs such as aspirin, naproxen, and ibuprofen.

Interestingly, at the time of its withdrawal, rofecoxib was the only coxib with clinical evidence of its superior gastrointestinal adverse effect profile over conventional NSAIDs. This was largely based on the VIGOR (Vioxx GI Outcomes Research) study, which compared the efficacy and adverse effect profiles of rofecoxib and naproxen. (Bombardier et al., 2000).

What are the claims filed in the lawsuit?

Carol Ernst claimed Vioxx was to blame for her husband Robert's death.

Mr Ernst, 59, had been taking the drug for eight months when he died of heart arrhythmia in his sleep in 2001. He was a marathon runner and triathlete who was using the drug to treat pain in his hands.

Merck insisted its drug was not to blame for Mr Ernst's death. It said he had suffered from an irregular heartbeat and clogged arteries and it was these factors which led to his death.

 
Britain.tv Directory    

Services
Add to Favourites
     
     
     
     
     
Useful Links